NasdaqCM - Nasdaq Real Time Price ? USD Elevai Labs Inc. (ELAB) Follow Compare 0.0178 -0.0036 (-16.82%) At close: November 6 at 4:00 PM EST 0.0172 -0.00 (-3.37%) After hours: 7:59 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Elevai Labs Inc.?Announces Update and Extension of Pending Offer to Exchange NEWPORT BEACH, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a leader in medical aesthetics, announced today that it is has amended and restated the Offer to Exchange, including extending the expiration date, of its previously announced offer (the “Offer”) to holders of the Company’s outstanding Common Stock (the “Common Stock”), to exchange up to 15,000,000 shares of Common Stock for up to 15,000,000 shares of the Company’s newly issued GlobeNewswire ? 2 days ago ELAB -16.82% Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity NEWPORT BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- EL-22 is a novel myostatin asset for the potential treatment of obesity in combination with existing GLP-1 medicinesThe Investigational New Drug application is planned for submission to the U.S. Food and Drug Administration (“FDA”) in 2025Muscle wasting is a common side effect of popular GLP-1 weight-loss medications, with no current approved treatments. EL-22 may offer an importation solution by preserving muscle mass while reducing fat m GlobeNewswire ? 15 days ago ELAB -16.82% Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity Preclinical results of EL-32 demonstrated statistically significant increases in grip strength, motor function and body composition in aged C57BL/6J mouse model.Elevai believes that EL-32 has the potential to treat obesity in combination with popular weight loss therapeutics, including GLP-1 receptor agonists, by preserving muscle mass while decreasing fat mass.Elevai plans to conduct additional animal studies to advance EL-32 towards an Investigational New Drug (IND) application. NEWPORT BEACH, GlobeNewswire ? 16 days ago ELAB -16.82% Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock NEWPORT BEACH, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, today announced the commencement of an offer to exchange up to 15,000,000 shares of its currently issued and outstanding common stock, par value $0.0001 per share (the “Common Stock”) for up to 15,000,000 shares of the Company’s newly issued Series B Preferred Stock (“Series B Preferred Stock”), with each share of Common Stock being exchangeable i GlobeNewswire ? last month ELAB -16.82% Sector Update: Health Care Stocks Fall Late Afternoon Sector Update: Health Care Stocks Fall Late Afternoon PREMIUM MT Newswires ? last month ELAB -16.82% REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonistsElevai Biosciences patent portfolio now includes 4 patent applications and 5 issued patents that provide adequate protection in focus markets NEWPORT BEACH, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, today announced the filing of two novel patent a GlobeNewswire ? last month ELAB -16.82% Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonistsElevai Biosciences patent portfolio now includes 4 patent applications and 5 issued patents that provide adequate protection in focus markets NEWPORT BEACH, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) ("Elevai" or the "Company"), a leader in medical aesthetics, today announced the filing of two novel patent a GlobeNewswire ? last month ELAB -16.82% Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic?Energy?Device In Collaboration with Renowned Aesthetic Medicine Expert Dr. Jennifer Pearlman, Elevai’s Study Will Investigate the Impact of Combining Exosome Skincare with Advanced Energy-Based Treatments for Optimal Skin Rejuvenation As the Global Energy-Based Aesthetic Device Market Is Projected to Reach $5.60 Billion by 2030, Elevai’s Study Seeks to Unlock the Full Potential of Combining Exosome Skincare Products with These Technologies for Enhanced Facial Rejuvenation NEWPORT BEACH, Calif., Oct. 02, 2024 GlobeNewswire ? last month ELAB -16.82% Altium Capital Management LP Acquires New Stake in Elevai Labs Inc On September 23, 2024, Altium Capital Management LP (Trades, Portfolio) marked a significant portfolio addition by purchasing 1,257,519 shares of Elevai Labs Inc (NASDAQ:ELAB). This acquisition not only diversifies Altium Capital's investment portfolio but also underscores its interest in the biotechnology sector. GuruFocus.com ? last month ELAB -16.82% Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB) New York, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered follow-on offering (the “Offering”) of approximately $8.0 million for its client Elevai Labs Inc. (NASDAQ: ELAB) (the “Company”), a pioneering force in medical aesthetics. The Offering was comprised of 28,571,425 shares of the Company’s common stock (or pre-fu GlobeNewswire ? last month ELAB -16.82% Top Midday Decliners Top Midday Decliners PREMIUM MT Newswires ? last month LUCYW ELAB -16.82% Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering NEWPORT BEACH, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced that it has priced a public offering with gross proceeds to the Company expected to be approximately $8.0 million, before deducting placement agent fees and other estimated expenses payable by the Company. The offering is a best-efforts offering, with no minimum amount of securities required to be sold. The offering is c GlobeNewswire ? last month ELAB -16.82% Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications Case Studies Highlight Potential of Elevai Exosome Technology in Melasma Care When Used with Laser Therapy. Early Results Show Synergistic Effects of Elevai Exosomes? and Laser Treatments for Melasma Improvement, With No Recurrence After Six Months. NEWPORT BEACH, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced positive case study results from patients undergoing laser therapy follo GlobeNewswire ? last month ELAB -16.82% Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology On Going Research Study Demonstrates Reversal of Hair Thinning and Inflammation with Elevai Exosomes?.Ongoing Research to Combine Exosome and Mitochondrial Technology for Enhanced Scalp and Hair Vitality. NEWPORT BEACH, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today announced data results from an on-going research study conducted in partnership with Carly Klein, President of the National Hai GlobeNewswire ? 2 months ago ELAB -16.82% Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBio? Y100? Mitochondrial Innovation and Elevai Exosomes? “One of the Biggest Innovations in Hair Loss We’ve Seen in Twenty-Five Years” - BosleyMD? Teams With Start-up Yuva Biosciences in National Launch of Breakthrough Technology1Elevai Labs and Yuva Biosciences Join Forces for Breakthrough in Hair and Scalp Care Technology NEWPORT BEACH, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics announces the filing of two innovative patents in collaboration with Yu GlobeNewswire ? 2 months ago ELAB -16.82% Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity? Topical Exosome Serum NEWPORT BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announces the completion of a clinical study examining the effectiveness of Elevai exosomes on facial appearance. The data, pending peer review, from the clinical study was internally reviewed by the Company, and the results show Elevai enfinity? to be safe and tolerable with significant improvement noted across many aspects of skin appe GlobeNewswire ? 2 months ago ELAB -16.82% Elevai Labs Second Quarter 2024 Earnings: US$0.077 loss per share (vs US$0.13 loss in 2Q 2023) Elevai Labs ( NASDAQ:ELAB ) Second Quarter 2024 Results Key Financial Results Revenue: US$605.5k (up 91% from 2Q 2023... Simply Wall St. ? 2 months ago ELAB -16.82% Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications Preliminary data from the research study in partnership with Dalhousie University demonstrates that Elevai’s hUMSC derived exosomes (“ELEVAI exosomes?”) contain over 800 proteins that are associated with wound healing, immunomodulation and remodeling of the skin’s extracellular matrix (“ECM”).ELEVAI exosomes? protein profile detected as part of this study was statistically significant and notably enriched compared to 54 previously published sets of exosome protein data.Data implies ELEVAI exosom GlobeNewswire ? 2 months ago ELAB -16.82% Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update NEWPORT BEACH, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update. Financial Results for the Three and Six Months Ended June 30, 2024 Revenue increased to $605,529 for the three months ended June 30, 2024, and $1,220,092 for the six months ended June 30, 2024, an increase of 91.3% and 165.6% respec GlobeNewswire ? 2 months ago ELAB -16.82% Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD Professor of Medicine at the University of California, Los Angeles (UCLA), where he serves as Director of the UCLA Metabolism Research Theme.Over 180 publications in the field of obesity & metabolism, along with multiple NIH-funded projects as Principal Investigator.Dr. Shirihai is a renowned researcher regularly invited as a keynote speaker at annual scientific conferences and has consulted for Johnson & Johnson, Bayer, AstraZeneca and Pfizer, among other healthcare companies. NEWPORT BEACH, Ca GlobeNewswire ? 3 months ago ELAB -16.82% Performance Overview Trailing total returns as of 11/6/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return ELAB S&P 500 YTD -99.03% +24.30% 1-Year -99.56% +30.65% 3-Year -99.56% +30.65%
